Risk of chemotherapy-induced febrile neutropenia with early discontinuation of pegfilgrastim prophylaxis in US clinical practice

PURPOSE: Accumulating evidence suggests that not all cancer chemotherapy patients who receive first-cycle pegfilgrastim prophylaxis continue to receive it in subsequent cycles and that these patients may be subsequently at higher risk of febrile neutropenia (FN). Additional evidence from US clinical...

Descripción completa

Detalles Bibliográficos
Autores principales: Weycker, Derek, Li, Xiaoyan, Barron, Rich, Li, Yanli, Reiner, Maureen, Kartashov, Alex, Figueredo, Jacqueline, Tzivelekis, Spiros, Garcia, Jacob
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2015
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4846701/
https://www.ncbi.nlm.nih.gov/pubmed/26670915
http://dx.doi.org/10.1007/s00520-015-3039-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4846701/
https://www.ncbi.nlm.nih.gov/pubmed/26670915
http://dx.doi.org/10.1007/s00520-015-3039-4

Ejemplares similares